State of play and clinical prospects of antibody gene transfer

Journal of Translational Medicine

Volumn 15, Issue 1, 2017, Pages

  Hollevoet, Kevin ^a   Declerck, Paul J ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; ADENOVIRUS VECTOR; MESSENGER RNA; MINICIRCLE DNA; MONOCLONAL ANTIBODY; NAKED DNA; ONCOLYTIC VIRUS; PLASMID DNA; RECOMBINANT ANTIBODY; RNA; VIRUS VECTOR; ANTIBODY; DNA; RECOMBINANT PROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL EVALUATION; CLINICAL OUTCOME; DNA VECTOR; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GENE DELIVERY SYSTEM; GENE EXPRESSION SYSTEM; GENE FUNCTION; GENE TRANSFER; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; INFLAMMATORY DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; RNA VECTOR; SIDE EFFECT; TRANSLATIONAL RESEARCH; VIRAL GENE DELIVERY SYSTEM; ANIMAL; GENE VECTOR; METABOLISM;

ANIMALS; ANTIBODIES; DNA; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; RECOMBINANT PROTEINS; RNA;

EID: 85020211708     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-017-1234-4     Document Type: Article

References (187)

1. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9-14.
2. Reichert JM. Antibodies to watch in 2017. MAbs. 2017;9(2):167-81.
3. Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev. 2015;41(10):859-67.
4. Sparrow E, Friede M, Sheikh M, Torvaldsen S. Therapeutic antibodies for infectious diseases. Bull World Health Organ. 2017;95(3):235-7.
5. Gils A, Bertolotto A, Mulleman D, Bejan-Angoulvant T, Declerck PJ. Biopharmaceuticals: reference products and biosimilars to treat inflammatory diseases. Ther Drug Monit. 2017. doi: 10.1097/FTD.0000000000000385.
6. Reichert JM. The antibody society: approved antibodies. http://www.antibodysociety.org/. Accessed 30 May 2017.
7. Webster RM. The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov. 2014;13(12):883-4.
8. Andrews A. Treating with checkpoint inhibitors: figure $1 million per patient. Am Health Drug Benefits. 2015;8:9.
9. Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol. 2016;2(1):19-21.
10. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs. 2009;1(5):443-52.
11. Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ. 2012;345:e8346.
12. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev. 2006;58(5-6):686-706.
13. Torgerson TR. Overview of routes of IgG administration. J Clin Immunol. 2013;33(Suppl 2):S87-9.
14. Leveque D. Subcutaneous administration of anticancer agents. Anticancer Res. 2014;34(4):1579-86.
15. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 2007;109(2):170-9.
16. Dronca RS, Dong H. Immunomodulatory antibody therapy of cancer: the closer, the better. Clin Cancer Res. 2015;21(5):944-6.
17. Neves V, Aires-da-Silva F, Corte-Real S, Castanho MA. Antibody approaches to treat brain diseases. Trends Biotechnol. 2016;34(1):36-48.
18. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
19. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy: immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;3(4):195-207.
20. Dumiak M. Making it to manufacturing. The potential success of broadly neutralizing monoclonal antibodies for HIV prevention, treatment, and possibly even a cure could come at a cost. IAVI Rep. 2014;18(2):4-7, 17.
21. Sanchez-Martin D, Sanz L, Alvarez-Vallina L. Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins. Curr Opin Biotechnol. 2011;22(6):924-30.
22. Suscovich TJ, Alter G. In situ production of therapeutic monoclonal antibodies. Expert Rev Vaccines. 2015;14(2):205-19.
23. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009;15(8):901-6.
24. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015;519(7541):87-91.
25. DiGiandomenico A, Patel A, Smith T, Keller A, Elliot ST, Wachter L, et al. DNA-delivery of monospecific and bispecific monoclonal antibodies targeting Pseudomonas Aeruginosa protect mice from lethal pneumonia. Am J Respir Crit Care Med. 2016:A7898.
26. Pang X, Ma F, Zhang P, Zhong Y, Zhang J, Wang T, et al. Treatment of human B-cell lymphomas using minicircle DNA vector expressing Anti-CD3/CD20 in a mouse model. Hum Gene Ther. 2017;28(2):216-25.
27. Verhelle A, Nair N, Everaert I, Van Overbeke W, Supply L, Zwaenepoel O, et al. AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. Hum Mol Genet. 2017;26(7):1353-64.
28. Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother. 2013;9(10):2253-62.
29. Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, et al. Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against Chikungunya virus. J Infect Dis. 2016;214(3):369-78.
30. Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology. 2016;5(10):e1220467.
31. Arafat WO, Gomez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 2002;9(4):256-62.
32. Afanasieva TA, Wittmer M, Vitaliti A, Ajmo M, Neri D, Klemenz R. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther. 2003;10(21):1850-9.
33. Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther. 2008;16(3):481-6.
34. Zuber C, Mitteregger G, Schuhmann N, Rey C, Knackmuss S, Rupprecht W, et al. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol. 2008;89(Pt 8):2055-61.
35. Wang YJ, Pollard A, Zhong JH, Dong XY, Wu XB, Zhou HD, et al. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging. 2009;30(3):364-76.
36. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA. 2009;106(31):12915-20.
37. Ryan DA, Mastrangelo MA, Narrow WC, Sullivan MA, Federoff HJ, Bowers WJ. Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector Improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther. 2010;18(8):1471-81.
38. Van Blarcom TJ, Sofer-Podesta C, Ang J, Boyer JL, Crystal RG, Georgiou G. Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Gene Ther. 2010;17(7):913-21.
39. Weibel S, Hofmann E, Basse-Luesebrink TC, Donat U, Seubert C, Adelfinger M, et al. Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J Transl Med. 2013;11:106.
40. Patel P, Kriz J, Gravel M, Soucy G, Bareil C, Gravel C, et al. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther. 2014;22(3):498-510.
41. Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G, et al. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest. 1995;96(6):2980-9.
42. Moayeri M, Tremblay JM, Debatis M, Dmitriev IP, Kashentseva EA, Yeh AJ, et al. Adenoviral expression of a bispecific VHH-based neutralizing agent that targets protective antigen provides prophylactic protection from anthrax in mice. Clin Vaccine Immunol. 2016;23(3):213-8.
43. Yang Z, Shi L, Yu H, Zhang Y, Chen K, Saint Fleur A, et al. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection. Pathog Dis. 2016;74(7):ftw078.
44. ®-a potent mRNA technology for passive and therapeutic immunization. Cold Spring Harbor Laboratory Meeting on RNA & Oligonucleotide Therapeutics: Cold Spring Harbor; 2017.
45. Mukherjee J, Dmitriev I, Debatis M, Tremblay JM, Beamer G, Kashentseva EA, et al. Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS ONE. 2014;9(8):e106422.
46. Deal CE, Balazs AB. Engineering humoral immunity as prophylaxis or therapy. Curr Opin Immunol. 2015;35:113-22.
47. Lu QL, Bou-Gharios G, Partridge TA. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. 2003;10(2):131-42.
48. Ratanamart J, Shaw JA. Plasmid-mediated muscle-targeted gene therapy for circulating therapeutic protein replacement: a tale of the tortoise and the hare? Curr Gene Ther. 2006;6(1):93-110.
49. Gene Therapy Clinical Trials Worldwide 2017. http://www.abedia.com/wiley/. Accessed 30 May 2017.
50. Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, Jayandharan GR. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Rev Med Virol. 2013;23(6):399-413.
51. Baldo A, van den Akker E, Bergmans HE, Lim F, Pauwels K. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination. Curr Gene Ther. 2013;13(6):385-94.
52. Vigna E, Pacchiana G, Mazzone M, Chiriaco C, Fontani L, Basilico C, et al. "Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res. 2008;68(22):9176-83.
53. Li M, Wu Y, Qiu Y, Yao Z, Liu S, Liu Y, et al. 2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice. Mol Ther. 2012;20(1):46-53.
54. Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13(6):421-33.
55. Tutykhina IL, Sedova ES, Gribova IY, Ivanova TI, Vasilev LA, Rutovskaya MV, et al. Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res. 2013;97(3):318-28.
56. Watanabe M, Boyer JL, Crystal RG. Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum Gene Ther. 2009;20(6):598-610.
57. Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, et al. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology. 2008;378(1):79-85.
58. Noel D, Pelegrin M, Kramer S, Jacquet C, Skander N, Piechaczyk M. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther. 2002;13(12):1483-93.
59. Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z, et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res. 2006;12(20 Pt 1):6179-85.
60. Deshane J, Siegal GP, Wang M, Wright M, Bucy RP, Alvarez RD, et al. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol Oncol. 1997;64(3):378-85.
61. Alvarez RD, Curiel DT. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. Hum Gene Ther. 1997;8(2):229-42.
62. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res. 2000;6(8):3081-7.
63. Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother. 2014;10(10):2875-84.
64. Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001;164(11):1612.
65. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14(3):316-27.
66. Chandler RJ, Sands M, Venditti CP. rAAV integration and genotoxicity: insights from animal models. Hum Gene Ther. 2017. doi: 10.1089/hum.2017.009.
67. Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood. 2012;119(13):3038-41.
68. Moran N. First gene therapy approved. Nat Biotechnol. 2012;30(12):1153.
69. Morrison C. $1-million price tag set for Glybera gene therapy. Nat Biotechnol. 2015:217-8.
70. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol. 2002;76(17):8769-75.
71. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol. 2005;23(5):584-90.
72. Limberis MP, Tretiakova A, Nambiar K, Wong G, Racine T, Crosariol M, et al. Adeno-associated virus serotype 9-expressed ZMapp in mice confers protection against systemic and airway-acquired ebola virus infection. J Infect Dis. 2016;214(12):1975-9.
73. Fukuchi K, Tahara K, Kim HD, Maxwell JA, Lewis TL, Accavitti-Loper MA, et al. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis. 2006;23(3):502-11.
74. Sudol KL, Mastrangelo MA, Narrow WC, Frazer ME, Levites YR, Golde TE, et al. Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease. Mol Ther. 2009;17(12):2031-40.
75. Kou J, Kim H, Pattanayak A, Song M, Lim JE, Taguchi H, et al. Anti-amyloid-beta single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer's disease mouse model. J Alzheimers Dis. 2011;27(1):23-38.
76. Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol. 2010;69(10):1078-85.
77. Kou J, Yang J, Lim JE, Pattanayak A, Song M, Planque S, et al. Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications. Mol Neurobiol. 2015;51(1):43-56.
78. Liu W, Zhao L, Blackman B, Parmar M, Wong MY, Woo T, et al. Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. J Neurosci. 2016;36(49):12425-35.
79. Limberis MP, Adam VS, Wong G, Gren J, Kobasa D, Ross TM, et al. Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med. 2013;5(187):187ra72.
80. Adam VS, Crosariol M, Kumar S, Ge MQ, Czack SE, Roy S, et al. Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. Clin Vaccine Immunol. 2014;21(11):1528-33.
81. Mao Y, Kiss S, Boyer JL, Hackett NR, Qiu J, Carbone A, et al. Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh. 10 coding for bevacizumab. Hum Gene Ther. 2011;22(12):1525-35.
82. De BP, Hackett NR, Crystal RG, Boyer JL. Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. Mol Ther. 2008;16(1):203-9.
83. Watanabe M, Boyer JL, Crystal RG. AAVrh. 10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther. 2010;17(8):1042-51.
84. Xie Y, Hicks MJ, Kaminsky SM, Moore MA, Crystal RG, Rafii A. AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecol Oncol. 2014;135(2):325-32.
85. Balazs AB, West AP, Jr. Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol. 2013:1-5.
86. Schnepp BC, Johnson PR. Vector-mediated antibody gene transfer for infectious diseases. Adv Exp Med Biol. 2015;848:149-67.
87. Fuchs SP, Desrosiers RC. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev. 2016;3:16068.
88. Brady JM, Baltimore D, Balazs AB. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev. 2017;275(1):324-33.
89. Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing antibodies for HIV-1 prevention or immunotherapy. N Engl J Med. 2016;375:2019-21.
90. Saunders KO, Wang L, Joyce MG, Yang ZY, Balazs AB, Cheng C, et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection. J Virol. 2015;89(16):8334-45.
91. Fuchs SP, Martinez-Navio JM, Piatak M Jr, Lifson JD, Gao G, Desrosiers RC. AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog. 2015;11(8):e1005090.
92. Martinez-Navio JM, Fuchs SP, Pedreno-Lopez S, Rakasz EG, Gao G, Desrosiers RC. Host anti-antibody responses following adeno-associated virus-mediated delivery of antibodies against HIV and SIV in Rhesus monkeys. Mol Ther. 2016;24(1):76-86.
93. Schnepp BC, Johnson PR. Adeno-associated virus delivery of broadly neutralizing antibodies. Curr Opin HIV AIDS. 2014;9(3):250-6.
94. Fuchs SP, Martinez-Navio JM, Gao G, Desrosiers RC. Recombinant AAV vectors for enhanced expression of authentic IgG. PLoS ONE. 2016;11(6):e0158009.
95. HIV immunity goes direct. Nat Biotechnol. 2014:397.
96. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642-62.
97. Ledford H. Cancer-fighting viruses win approval. Nature. 2015;526:622-3.
98. Liu TC, Thorne SH, Kirn DH. Oncolytic adenoviruses for cancer gene therapy. Methods Mol Biol. 2008;433:243-58.
99. Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen CH, et al. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res Treat. 2014;148(3):489-99.
100. Buckel L, Advani SJ, Frentzen A, Zhang Q, Yu YA, Chen NG, et al. Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. Int J Cancer. 2013;133(12):2989-99.
101. Adelfinger M, Bessler S, Frentzen A, Cecil A, Langbein-Laugwitz J, Gentschev I, et al. Preclinical testing oncolytic vaccinia virus strain GLV-5b451 expressing an anti-VEGF single-chain antibody for canine cancer therapy. Viruses. 2015;7(7):4075-92.
102. Patil SS, Gentschev I, Adelfinger M, Donat U, Hess M, Weibel S, et al. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. PLoS ONE. 2012;7(10):e47472.
103. Huang T, Wang H, Chen NG, Frentzen A, Minev B, Szalay AA. Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy. Mol Ther Oncolytics. 2015;2:15003.
104. Liikanen I, Tahtinen S, Guse K, Gutmann T, Savola P, Oksanen M, et al. Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer. Mol Cancer Ther. 2016;15(9):2259-69.
105. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559-67.
106. Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 2012;19(10):988-98.
107. Du T, Shi G, Li YM, Zhang JF, Tian HW, Wei YQ, et al. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 2014;21(8):340-8.
108. Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther. 2014;22(11):1949-59.
109. Tanoue K, Rosewell Shaw A, Watanabe N, Porter CE, Rana B, Gottschalk S, et al. Armed oncolytic adenovirus expressing PD-L1 mini-body enhances anti-tumor effects of chimeric antigen receptor T-cells in solid tumors. Cancer Res. 2017;77(8):2040-51.
110. Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24(2):59-67.
111. Ratanamart J, Huggins CG, Shaw JA. Transgene expression in mononuclear muscle cells not infiltrating inflammatory cells following intramuscular plasmid gene electrotransfer. J Gene Med. 2010;12(4):377-84.
112. Tseng YS, Agbandje-McKenna M. Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front Immunol. 2014;5:9.
113. Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol. 2014;5:350.
114. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465-8.
115. Hardee CL, Arevalo-Soliz LM, Hornstein BD, Zechiedrich L. Advances in non-viral DNA vectors for gene therapy. Genes. 2017;8(2):65.
116. Faurez F, Dory D, Le Moigne V, Gravier R, Jestin A. Biosafety of DNA vaccines: new generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine. 2010;28(23):3888-95.
117. Heller R, Heller LC. Gene electrotransfer clinical trials. Adv Genet. 2015;89:235-62.
118. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5896-903.
119. Evans C, Hannaman D. Current status of electroporation technologies for vaccine delivery. In: Singh Manmohan, editor. Novel immune potentiators and delivery technologies for next generation vaccines. Springer: Berlin; 2013. p. 185-215.
120. Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, et al. Tolerability of intramuscular and intradermal delivery by CELLECTRA adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother. 2013;9(10):2246-52.
121. Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Ther. 2007;15(12):2063-9.
122. Meacham JM, Durvasula K, Degertekin FL, Fedorov AG. Physical methods for intracellular delivery: practical aspects from laboratory use to industrial-scale processing. J Lab Autom. 2014;19(1):1-18.
123. Ibraheem D, Elaissari A, Fessi H. Gene therapy and DNA delivery systems. Int J Pharm. 2014;459(1-2):70-83.
124. Simcikova M, Prather KL, Prazeres DM, Monteiro GA. Towards effective non-viral gene delivery vector. Biotechnol Genet Eng Rev. 2015;31(1-2):82-107.
125. Vandermeulen G, Marie C, Scherman D, Préat V. New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol Ther. 2011;19(11):1942-9.
126. Takahashi Y, Nishikawa M, Takakura Y. Development of safe and effective nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector. Front Biosci. 2012;4:133-41.
127. Chen ZY, He CY, Meuse L, Kay MA. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther. 2004;11(10):856-64.
128. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. In: Wolfgang W, Ulrike SS, editors. Methods in molecular biology, gene therapy of cancer, vol. 542. New York: Humana Press; 2009. p. 87-104.
129. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther. 2003;8(3):495-500.
130. Kobelt D, Schleef M, Schmeer M, Aumann J, Schlag PM, Walther W. Performance of high quality minicircle DNA for in vitro and in vivo gene transfer. Mol Biotechnol. 2013;53(1):80-9.
131. Perez N, Bigey P, Scherman D, Danos O, Piechaczyk M, Pelegrin M. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther. 2004;2(1):2.
132. Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther. 2004;9(3):328-36.
133. Kitaguchi K, Toda M, Takekoshi M, Maeda F, Muramatsu T, Murai A. Immune deficiency enhances expression of recombinant human antibody in mice after nonviral in vivo gene transfer. Int J Mol Med. 2005;16(4):683-8.
134. Yamazaki T, Nagashima M, Ninomiya D, Arai Y, Teshima Y, Fujimoto A, et al. Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids. Jpn J Infect Dis. 2011;64(1):40-9.
135. McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase: increased expression with reduced muscle damage. Gene Ther. 2001;8(16):1264-70.
136. Flingai S, Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE, et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep. 2015;5:12616.
137. Cooch N, Guibinga G, Chen J, Reed C, Ramos S, Smith T, et al. Description of structural modifications of DNA vector encoded monoclonal antibodies (DMAbs) to improve in vivo expression levels after intramuscular injection and electroporation. American Society for Gene and Cell Therapy Annual Meeting; Washington, DC, May 9-14, 2017.
138. Guibinga GH, Chen J, Reed C, Cooch N, Ramos S, Yan J, Smith T, Patel A, et al. Functional assessment of structural reformatting and protein engineering strategies for therapeutic gene transfer synthetic DNA-plasmid encoding antibodies against ebola virus disease (EVD). American Society for Gene and Cell Therapy Annual Meeting; Washington DC, May 9-14, 2017.
139. Schultheis K, Smith TRF, Ramos S, Schommer N, Jian J, Yung B, et al. Optimization of gene transfer protocol achieves robust in vivo expression of DNA-based monoclonal antibodies (DMAbs) in small and large animals. American Society for Gene and Cell Therapy Annual Meeting; Washington DC, May 9-14, 2017.
140. Goodfellow R. Scancell's vaccine SCIB1 could help to prevent recurrence of melanoma. Immunotherapy. 2015;7(9):953-5.
141. Xue W, Brentville VA, Symonds P, Cook KW, Yagita H, Metheringham RL, et al. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget. 2016;7(50):83088-100.
142. Scancell Limited. SCIB1 clinical study report 2017. http://www.scancell.co.uk/news/regulatory-news/scib1-clinical-study-report. Accessed 30 May 2017.
143. Yi H, Kim Y, Kim J, Jung H, Rim YA, Jung SM, et al. A new strategy to deliver synthetic protein drugs: self-reproducible biologics using minicircles. Sci Rep. 2014;4:5961.
144. Lim SW, Kim YK, Park N, Jin L, Jin J, Doh KC, et al. Application of minicircle technology of self-reproducing synthetic protein drugs in preventing skin allograft rejection. Ann Transpl. 2015;20:430-40.
145. Kim Y, Yi H, Jung H, Rim YA, Park N, Kim J, et al. A dual target-directed agent against interleukin-6 receptor and tumor necrosis factor alpha ameliorates experimental arthritis. Sci Rep. 2016;6:20150.
146. Rim YA, Yi H, Kim Y, Park N, Jung H, Kim J, et al. Self in vivo production of a synthetic biological drug CTLA4Ig using a minicircle vector. Sci Rep. 2014;4:6935.
147. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics: developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759-80.
148. Broderick KE, Humeau LM. Enhanced delivery of DNA or RNA vaccines by electroporation. Methods Mol Biol. 2017;1499:193-200.
149. Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345-51.
150. Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630.
151. Fang J, Yi S, Simmons A, Tu GH, Nguyen M, Harding TC, et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther. 2007;15(6):1153-9.
152. Guo ZS, Li Q, Bartlett DL, Yang JY, Fang B. Gene transfer: the challenge of regulated gene expression. Trends Mol Med. 2008;14(9):410-8.
153. Cai H, Sun L, Miao J, Krishman S, Lebel F, Barrett JA. Plasma pharmacokinetics of veledimex, a small-molecule activator ligand for a proprietary gene therapy promoter system, in healthy subjects. Clin Pharmacol Drug Dev. 2016. doi: 10.1002/cpdd.287.
154. Hojman P, Spanggaard I, Olsen CH, Gehl J, Gissel H. Calcium electrotransfer for termination of transgene expression in muscle. Hum Gene Ther. 2011;22(6):753-60.
155. Schellekens H. The immunogenicity of therapeutic proteins. Discov Med. 2010;9(49):560-4.
156. Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther. 2009;17(10):1733-42.
157. Boisgerault F, Mingozzi F. The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer. Curr Gene Ther. 2015;15(4):381-94.
158. Shimizu Y, Meunier L, Hendershot LM. pERp1 is significantly up-regulated during plasma cell differentiation and contributes to the oxidative folding of immunoglobulin. Proc Natl Acad Sci USA. 2009;106(40):17013-8.
159. Weeratna RD, Wu T, Efler SM, Zhang L, Davis HL. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther. 2001;8(24):1872-8.
160. Martinez-Navio JM, Fuchs SP, Pedreno-Lopez S, Rakasz EG, Gao G, Desrosiers RC. Host anti-antibody responses following AAV-mediated delivery of antibodies against HIV and SIV in Rhesus monkeys. Mol Ther. 2016;24(1):76-86.
161. Ho SC, Koh EY, van Beers M, Mueller M, Wan C, Teo G, et al. Control of IgG LC:HC ratio in stably transfected CHO cells and study of the impact on expression, aggregation, glycosylation and conformational stability. J Biotechnol. 2013;165(3-4):157-66.
162. Davies SL, O'Callaghan PM, McLeod J, Pybus LP, Sung YH, Rance J, et al. Impact of gene vector design on the control of recombinant monoclonal antibody production by Chinese hamster ovary cells. Biotechnol Prog. 2011;27(6):1689-99.
163. Jefferis R. Characterization of biosimilar biologics: the link between structure and functions. In: Endrenyi L, Declerck P, Chow S-C, editors. Biosimilar drug product development. Boca Raton: CRC Press; 2017. p. 109-50.
164. Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev. 2016;S0169-409X(16):30317-9.
165. Saxena A, Wu D. Advances in therapeutic Fc engineering-modulation of IgG-associated effector functions and serum half-life. Front Immunol. 2016;7:580.
166. Sofer-Podesta C, Ang J, Hackett NR, Senina S, Perlin D, Crystal RG, et al. Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun. 2009;77(4):1561-8.
167. Pereboev A, Borisevich V, Tsuladze G, Shakhmatov M, Hudman D, Kazachinskaia E, et al. Genetically delivered antibody protects against West Nile virus. Antiviral Res. 2008;77(1):6-13.
168. Han T, Abdel-Motal UM, Chang DK, Sui J, Muvaffak A, Campbell J, et al. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS ONE. 2012;7(9):e44455.
169. Lv F, Qiu Y, Zhang Y, Liu S, Shi J, Liu Y, et al. Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice. Cancer Lett. 2011;302(2):119-27.
170. Shi J, Liu Y, Zheng Y, Guo Y, Zhang J, Cheung PT, et al. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice. Cancer Res. 2006;66(24):11946-53.
171. Ho DT, Wykoff-Clary S, Gross CS, Schneider D, Jin F, Kretschmer PJ, et al. Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer Gene Ther. 2009;16(2):184-94.
172. Watanabe M, Boyer JL, Hackett NR, Qiu J, Crystal RG. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice. Hum Gene Ther. 2008;19(3):300-10.
173. Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci. 2009;29(43):13589-602.
174. Yang J, Pattanayak A, Song M, Kou J, Taguchi H, Paul S, et al. Muscle-directed anti-Abeta single-chain antibody delivery via AAV1 reduces cerebral Abeta load in an Alzheimer's disease mouse model. J Mol Neurosci. 2013;49(2):277-88.
175. Moda F, Vimercati C, Campagnani I, Ruggerone M, Giaccone G, Morbin M, et al. Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice. Prion. 2012;6(4):383-90.
176. de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014;6(254):254ra129.
177. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012;481(7379):81-4.
178. Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med. 2014;20(3):296-300.
179. Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA. 2013;110(41):16538-43.
180. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol. 2013;31(7):647-52.
181. Deal C, Balazs AB, Espinosa DA, Zavala F, Baltimore D, Ketner G. Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc Natl Acad Sci USA. 2014;111(34):12528-32.
182. Hicks MJ, Rosenberg JB, De BP, Pagovich OE, Young CN, Qiu JP, et al. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci Transl Med. 2012;4(140):140ra87.
183. Rosenberg JB, Hicks MJ, De BP, Pagovich O, Frenk E, Janda KD, et al. AAVrh. 10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther. 2012;23(5):451-9.
184. Li J, Olvera AI, Akbari OS, Moradian A, Sweredoski MJ, Hess S, et al. Vectored antibody gene delivery mediates long-term contraception. Curr Biol. 2015;25(19):R820-2.
185. Hollevoet K, Geukens N, Velde GV, Declerck P. Long-term in vivo expression of trastuzumab following intramuscular electrotransfer of the encoding DNA in mice. J Immunother Cancer. 2015;3(Suppl 1):O5.
186. Muthumani K, Chung C, Agarwal S, Plyler R, Kudchodkar S, Flingai S, et al. In vivo expression of plasmid encoded IgG for PD-1 or LAG3 by synthetic DNA as a new tool for cancer immunotherapy. Mol Ther. 2016;24:159.
187. Patel A, Davis C, Park DH, Smith TRF, Leung A, Tierney K, et al. DNA-monoclonal antibody gene delivery against ebola virus disease, an in vivo DNA vectored approach for achieving sustained, transient serum levels of protective IgG. American Society for Gene and Cell Therapy Annual Meeting; Washington DC, May 9-14, 2017.